FSD Pharma (NASDAQ:HUGE) just reported results for the second quarter of 2024. FSD Pharma reported earnings per share of -8 cents. This was below the analyst estimate for EPS of -6 cents.

Supervisory Board Freya Pharma’s new Supervisory Board From left to right: Manuel Voll, James E. Hattersley and Inez de ...

or the Company], a pharmaceutical company dedicated to developing effective therapies for women diagnosed with Female Sexual Disorders (FSD), today announced the formation of its Supervisory Board ...